Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
3 min read
Vorolanib - Betta's New Multitargeted Drug for Kidney Cancer Treatment
21 July 2023
Vorolanib is a new generation of multi target kinase inhibitors with a completely new chemical structure.
R&D Pipeline
4 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of Alexion 's 88 Drug Pipelines
21 July 2023
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company that was founded in 1992 and is headquartered in Connecticut, United States.
R&D Pipeline
3 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of CSPC Pharmaceutical 's 119 Drug Pipelines
21 July 2023
CSPC Pharmaceutical Group Ltd. is a pharmaceutical organization based in Hong Kong SAR, China. It was founded in 1997 and has since become a prominent player in the biomedicine industry.
Advanced Tech.
5 min read
A Sweet Shield Against Chemotherapy's Harsh Side Effects: The Surprising Power of Mannose
21 July 2023
The potential use of mannose as a supplement to inhibit gasdermin-mediated pyroptosis by activating AMPK, as described in the study published on Cell Research, presents a novel and promising avenue for the development of cancer treatments, offering a promising approach to mitigating the harsh side effects of chemotherapy.
R&D Pipeline
4 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of Ipsen's 126 Drug Pipelines
20 July 2023
Ipsen SA is a pharmaceutical organization that was founded in 1929 and is based in France.
R&D Pipeline
4 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of Aurobindo's 22 Drug Pipelines
20 July 2023
Aurobindo Pharma Ltd. is a pharmaceutical organization that was founded in 1986 and is based in Andhra Pradesh, India.
Advanced Tech.
5 min read
Boosting anti-PD-1 PD-L1 therapy by targeting YTHDF1
20 July 2023
YTH domain-containing family protein 1 (YTHDF1) is a translation-promoting m6A reader that targets mRNAs in the cytoplasm and contributes to tumor progression by regulating cell proliferation, DNA damage, and immunity.
R&D Pipeline
3 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of STADA Arzneimittel's 19 Drug Pipelines
20 July 2023
STADA Arzneimittel AG is a pharmaceutical organization that was founded in 1895 and is based in Hessen, Germany.
R&D Pipeline
3 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of Jazz's 61 Drug Pipelines
20 July 2023
Jazz Pharmaceuticals Plc is a pharmaceutical company that was founded in 2003 and is headquartered in Dublin, Ireland.
Advanced Tech.
5 min read
Breaking Through the Blood-Brain Barrier: P-Selectin-Targeted Nanocarriers Promote Active Crossing
20 July 2023
Fucoidan-based nanocarriers can actively transport therapeutic cargo across tumor endothelium, allowing for targeted delivery to the tumor microenvironment. This approach holds immense potential to revolutionize therapeutic outcomes for diseases with an intact BBB, such as SHH-MB, and could usher in a new era of improved therapies for a multitude of brain diseases.
Advanced Tech.
6 min read
The Dual Boom of Bispecific Antibodies: Market and Drug Discovery Pipeline
18 July 2023
They have gained broad potential in preclinical and clinical investigations in a variety of tumor types following regulatory approval of newly developed technologies involving bispecific and multispecific antibodies.
Valuable Targets
10 min read
The novel class of USP1 inhibitors opens up new frontiers for the treatment of cancers and diabetes
17 July 2023
the discovery and development of USP1 inhibitors certainly open up new frontiers for the treatment of a variety of diseases, including cancer, diabetes, and potentially even more.